Protein Biomarker Discovery, Assay Development and Qualification NextGen Sciences Inc is a growing CRO applying mass spectrometry technology to develop quantitative protein assays for the discovery and qualification of protein biomarkers for clients across the pharmaceutical, biotechnology and diagnostics industries. Our first mission is to become a leading player in the growing oncology and central nervous system (CNS) biomarker markets. We are positioned for commercial growth through sale of our products and services, and via partnerships with companies and academic/clinical organisations. Our second mission is to establish a diagnostic business stream in the areas of early diagnosis, prognosis and stratification of patients for personalised healthcare. This approach will be supported through a biomarker IP strategy developed through partnerships and collaborations with key scientists and clinicians. The company has worked with 16 of the top 20 pharmaceutical and biotechnology companies and with many clients from the small pharma, biotech and academic sectors. NextGen Sciences Inc (Ann Arbor, MI, USA) is a subsidiary of NextGen Group PLC, London, UK (AIM: NGG).